Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › End Stage Renal Disease

End Stage Renal Disease

Part of Chronic Kidney Disease

18 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for End Stage Renal Disease

136 trials tracked for End Stage Renal Disease: 33 in phase 3 or 4 and 14 with published results. The most-cited published study has 296 citations.

136Trials tracked
33Phase 3 & 4
0Recruiting
14With published results
Phase distribution
Phase 4 17 Phase 3 16 Phase 2 36 Phase 1 12 Other / NA 55
  1. Phase 4 Exploring Renal Transplants Using Hepatitis C Infected Donors for HCV-negative Recipients Completed · 296 cited
  2. Phase 3 Ombitasvir/ABT-450/Ritonavir and Dasabuvir With or Without Ribavirin in HCV Genotype 1-Infected Adults With Chronic Kidney Disease Completed · 278 cited
  3. Phase 4 Trial to Evaluate Anticoagulation Therapy in Hemodialysis Patients With Atrial Fibrillation Completed · 226 cited
  4. Phase 3 A Trial of Sertraline vs. CBT for End-stage Renal Disease Patients With Depression {ASCEND} Completed · 115 cited
  5. Phase 3 Journeys to Wellness: A Transplant Candidate Study Completed · 67 cited
  6. Phase 4 Kidney Transplants in Hepatitis C Negative Recipients With Hepatitis C Viremic Donors Completed · 49 cited
Show 44 more trials
  1. Phase 4 Patiromer Efficacy to Reduce Episodic Hyperkalemia in End Stage Renal Disease Patients Completed · 46 cited
  2. Phase 4 Study Response of 13-valent Conjugate Pneumococcal Vaccine in Patients With End Stage Renal Disease Completed · 37 cited
  3. Phase 3 Safety and Efficacy Study of the Venous Window Needle Guide to Access Arteriovenous (AV)Fistulae Completed · 29 cited
  4. Phase 3 Short and Long-Term Effectiveness of Existing Insomnia Therapies for Patients Undergoing Hemodialysis Completed · 22 cited
  5. Phase 3 A Study to Evaluate the Safety of Paricalcitol Capsules in Pediatric Subjects Ages 10 to 16 With Stage 5 Chronic Kidney Disease Receiving Peritoneal Dialysis or Hemodialysis Completed · 19 cited
  6. Phase 4 A Long-Term Study of Tenapanor Alone or in Combination With Sevelamer in Patients With CKD on Dialysis and HP Completed · 18 cited
  7. Phase 3 Comparison of the Human Acellular Vessel (HAV) With ePTFE Grafts as Conduits for Hemodialysis Completed · 13 cited
  8. Phase 4 Effect of Dialysis on the Pharmacokinetics of Telavancin in Patients With Chronic Kidney Disease Stage 5 Completed · 3 cited
  9. Phase 4 Renal Transplants in Hepatitis C Negative Recipients With Nucleic Acid Positive Donors Completed
  10. Phase 4 Trial to Evaluate Safety and Tolerability of Tacrolimus Extended-Release (Astagraf XL) in Human Leukocyte Antigen (HLA) Sensitized Kidney Transplant Recipients Completed
  11. Phase 4 Triferic AVNU Infusion Via Freedom Pump During Hemodialysis Completed
  12. Phase 4 Ertapenem Pharmacokinetics in Patients in Continuous Ambulatory Peritoneal Dialysis Completed
  13. Phase 4 Improved Induction and Maintenance Immunosuppression in Kidney Transplantation Completed
  14. Phase 4 Safety and Effects of Supplementation With Ergocalciferol on Erythropoietin Dosing in Hemodialysis Patients Completed
  15. Phase 4 Panel Reactive Antibody (PRA) Reduction in Sensitized Patients Awaiting Renal Transplantation Completed
  16. Phase 4 Pharmacokinetics of Single-Dose Oral Ranolazine in Hemodialysis Patients Completed
  17. Phase 4 ADVANCE: Study to Evaluate Cinacalcet Plus Low Dose Vitamin D on Vascular Calcification in Subjects With Chronic Kidney Disease Receiving Hemodialysis Completed
  18. Phase 4 A Research Study for Patients With End-Stage Renal Disease (ESRD) Completed
  19. Phase 3 A Long-Term Safety Extension Trial of Ferric Citrate in Patients With End-Stage Renal Disease (ESRD) on Dialysis Completed
  20. Phase 3 Efficacy of Sirolimus-Based, Steroid Avoidance Immunosuppression African Americans Completed
  21. Phase 3 Extended Release Tacrolimus vs. Twice-Daily Tacrolimus Completed
  22. Phase 3 Trial to Evaluate the Sirolimus-Eluting Collagen Implant on AV Fistula Outcomes Completed
  23. Phase 3 A Sleep Laboratory Study to Investigate the Safety and Efficacy of the Rotigotine Skin Patch in Subjects With Restless Legs Syndrome and End-Stage Renal Disease Requiring Hemodialysis Completed
  24. Phase 3 Safety Study of Soluble Ferric Pyrophosphate (SFP) in Dialysate in CKD Patients Receiving Chronic Hemodialysis Completed
  25. Phase 3 A 4-Week Dose-Ranging and Efficacy Trial of KRX-0502 (Ferric Citrate) in Patients With End-Stage Renal Disease Completed
  26. Phase 3 Treatment of Autonomous Hyperparathyroidism in Post Renal Transplant Recipients Completed
  27. Phase 3 Evaluation of the GORE® ACUSEAL Vascular Graft for Hemodialysis Access Completed
  28. Phase 2 Safety and Efficacy Study of AB002 (E-WE Thrombin) in End Stage Renal Disease Patients on Chronic Hemodialysis Completed
  29. Phase 2 C1INH Inhibitor Preoperative and Post Kidney Transplant to Prevent DGF & IRI Completed
  30. Phase 2 A Safety and Tolerability Study of Zerenex (Ferric Citrate) in Patients With End-Stage Renal Disease (ESRD) Completed
  31. Phase 2 Determine the Safety/Efficacy of Ticagrelor for Maintaining Patency of Arterio-Venous Fistulae Created for Hemodialysis Completed
  32. Phase 2 Bone Mass and Strength After Kidney Transplantation Completed
  33. Phase 2 Pharmacokinetics and Optimal Dose of Ertapenem in Hemodialysis Patients Completed
  34. Phase 2 Equivalence of Triferic® (Ferric Pyrophosphate Citrate) Administered Via Hemodialysate and Intravenously to Adult CKD-5HD Patients Completed
  35. Phase 2 Use of Immune Globulin Plus Rituximab for Desensitization in Highly HLA Sensitized Patients Awaiting Deceased Donor Kidney Transplantation Completed
  36. Phase 2 Safety and Dose Finding Study of Xigris in Hemodialysis Patients Completed
  37. Phase 2 16-Week Repeat Oral Dose Study of AKB-6548 for Anemia in Participants With End Stage Renal Disease (ESRD) Requiring Chronic Hemodialysis Completed
  38. Phase 2 Study to Investigate the Safety of a Drug Called Osocimab at Low and High Doses in Adult Patients With Kidney Failure Requiring Regular Hemodialysis Completed
  39. Phase 2 The Effects of Patiromer on Serum Potassium Level and Gut Microbiome of ESRD Patients With Hyperkalemia Completed
  40. Phase 2 Safety Trial of Single Versus Multiple Dose Thymoglobulin Induction in Kidney Transplantation Completed
  41. Phase 2 Study of the Effect of Intradialytic Vasopressin on Chronic Hypertension in Patients With End Stage Renal Disease Completed
  42. Phase 2 Renal Allograft Tolerance Through Mixed Chimerism Completed
  43. Phase 2 Global Study of MK-2060 (Anti-Factor XI Monoclonal Antibody) in Participants With End Stage Renal Disease Receiving Hemodialysis (FXI Hemodialysis Study) (MK-2060-007) Completed
  44. Phase 2 The Effect of an Antibiotic on the Production of Uremic Toxins by the Gut Microbiome Completed

Showing the 50 most-cited and recently-updated of 136 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found Updated — new results For clinicians

End Stage Renal Disease: what the trials found

Cinacalcet was shown to significantly improve mineral metabolism in patients with chronic kidney disease, specifically resulting in a higher number of participants achieving mean PTH ≤ 300 pg/mL 20, and a significant increase in the number of patients achieving both Ca x P < 55 mg^2/dL^2 and iPTH ≤ 300 pg/mL 20. Additionally, cinacalcet was associated with an absolute reduction in PTH levels 21.

Patiromer significantly reduced the total number of episodes of serum potassium ≩ 5.5 mEq/L compared to the control group 8.

In patients with end-stage renal disease on dialysis, the 13-valent conjugate pneumococcal vaccine resulted in various changes from baseline in antibody concentrations 9.

Recent results — preliminary, needs further review

  • • The Ellipsys Vascular Access System demonstrated a cumulative patency of 99.1% over 12 months with a low early occlusion rate of 1.5% 1.
  • • Educational interventions regarding kidney donation and transplant significantly improved knowledge regarding living donor kidneys 2.
  • ‣ Patient activation programs were evaluated for their impact on dialysis adherence, showing mean weekly minutes missed ranging from approximately 4.89 to 5.28 4.

For the clinician treating this condition

  • Cinacalcet is effective for managing secondary hyperparathyroidism and mineral metabolism in renal patients [20, 21].
  • Patiromer is an effective intervention for controlling hyperkalemia by reducing the frequency of high potassium episodes 8.
  • The Ellipsys Vascular Access System shows high patency rates for vascular access in dialysis patients 1.

AI synthesis of 7 cited trials, updated Jun 21, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Total IgG Concentration Linked to Anemia in Hemodialysis Patients
Diabetes & Endocrinology Cohort
Total IgG Concentration Linked to Anemia in Hemodialysis Patients Is low immunity linked to anemia in dialysis patients, or just age?
This cross-sectional study included 351 participants, comprising 179 dialysis patients and 172 healthy controls.
Dialysis patients with weaker overall immune defenses are more likely to have anemia, while protection from chickenpox offers little clue ab…
Frontiers Apr 16, 2026
Cryopreserved venous allografts increased cold ischemia time in living-donor kidney transplant recipients
Orthopedics & Sports Medicine Cohort
Cryopreserved venous allografts increased cold ischemia time in living-donor kidney transplant recipients Does stretching a kidney vein during transplant add dangerous wait time for the organ?
This preliminary cohort study examined living-donor kidney transplant recipients and donors at two regional university hospitals.
Using cryopreserved veins to fix short donor kidney vessels adds nearly two hours to the organ's wait time before it reaches the recipient.
Frontiers Apr 16, 2026
Retrospective study identifies predictors for dialysis access steal syndrome in ESRD patients
Nephrology Cohort
Retrospective study identifies predictors for dialysis access steal syndrome in ESRD patients Study identifies factors that may predict dialysis access steal syndrome risk
A retrospective cohort study of 324 ESRD patients found 26.5% developed dialysis access steal syndrome (DASS).
A new model predicts dialysis access steal syndrome risk using patient frailty, body mass, and surgeon experience to help doctors spot dange…
Frontiers Apr 8, 2026
Serenity therapy reduces symptoms and improves coping in geriatric hemodialysis patients
Nephrology RCT
Serenity therapy reduces symptoms and improves coping in geriatric hemodialysis patients Can a calming therapy ease the heavy burden of dialysis for older patients?
An 80-patient randomized controlled trial in Egyptian geriatric hemodialysis patients found serenity therapy significantly reduced hemodialy…
Serenity therapy significantly reduced dialysis symptoms and improved emotional coping for older patients in a new Egyptian study.
Apr 7, 2026
ESRD patients experienced 8.7-12.9 excess deaths per 1,000 during early U.S. COVID-19 pandemic
Infectious Disease
ESRD patients experienced 8.7-12.9 excess deaths per 1,000 during early U.S. COVID-19 pandemic How many more dialysis patients died during the first COVID-19 wave?
An observational analysis of 798,611 U.S.
During the first seven months of the pandemic, roughly 7,000 to 10,300 more dialysis patients died than expected in a normal year.
CDC Apr 6, 2026
Retrospective study of semaglutide in 17 patients with type 2 diabetes and end-stage renal disease
Diabetes & Endocrinology Cohort
Retrospective study of semaglutide in 17 patients with type 2 diabetes and end-stage renal disease Can a diabetes drug help people with kidney failure? A small study looks for clues
A retrospective cohort study of 17 adults with T2DM and ESRD (including those on hemodialysis) found descriptive reductions in HbA1c (-0.31%…
A small study found that injectable semaglutide helped adults with kidney failure lose an average of 12.6 kilograms while reducing insulin n…
Frontiers Apr 1, 2026

Questions about End Stage Renal Disease

Does symptom distress negatively affect quality of life in hemodialysis patients?

Yes, symptom distress — including post-dialysis fatigue, itching, anxiety, and depression — significantly reduces quality of life in hemodialysis patients.

Full answer →
How does nutrition education improve quality of life for adults with End Stage Renal Disease on dialysis?

Nutrition education significantly improves quality of life and dietary knowledge for adults on dialysis, according to a meta-analysis of 44 studies.

Full answer →